Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET

Company Participants

Carrie Mendivil - IR

Sujal Patel - Co-Founder & CEO

Parag Mallick - Co-Founder & Chief Scientist

Anna Mowry - CFO

Conference Call Participants

Matt Sykes - Goldman Sachs

Dan Brennan - TD Cowen

Operator

Good day, and thank you for standing by. Welcome to Nautilus Q4 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Carrie Mendivil, Investor Relations. Please go ahead.

Carrie Mendivil

Thank you. Earlier today, Nautilus released financial results for the quarter and full year ended December 31, 2023. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an e-mail to Investor Relations at investorrelations@nautilus.bio. Joining me today from Nautilus are Sujal Patel, Co-Founder and CEO; Parag Mallick, Co-Founder and Chief Scientist; and Anna Mowry, Chief Financial Officer.

Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, February 28, 2024.

With that, I'll turn the call over to Sujal.

Sujal Patel

Thanks, Carrie. Good morning, and thank you to everyone for joining us today. This morning, we'll share our results for the fourth quarter and full year 2023 and provide an update on recent activities.

But first, I want to thank our employees, our partners and our investors, creating a platform capable of enabling researchers to explore the mysteries and the potential of the proteome is very much a team effort. It requires strong alignment up and down the organization, vision, persistence and an unwavering commitment to our goal of improving human health. I'm grateful for the extraordinary work the entire team did in 2023 and for how they've kicked off 2024 stronger than ever.